On January 6, 2022 Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics designed to elicit a potent and durable immune response in the tumor microenvironment, reported that Claire Mazumdar, Ph.D., MBA, Chief Executive Officer of Bicara Therapeutics, will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference, to be held virtually January 10-13, 2022 (Press release, Bicara Therapeutics, JAN 6, 2022, View Source [SID1234598367]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details:
Date: Monday, January 10, 2022
Time: 8:00 a.m. ET